Transkaryotic Therapies, Inc. (TKT) is a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and is developing products for Hunter syndrome and Gaucher disease.

In addition to the company's focus in the area of rare diseases, TKT is preparing to commercialize its Gene-Activated erythropoietin product, Dynepo, in Europe, which is approved for commercial sale. There are also several early stage development or exploratory projects that will not be developed internally by TKT. These projects represent significant licensing opportunities. Visit our website for more detail on these exciting projects.

In addition to its headquarters and manufacturing facility in Cambridge, Massachusetts, TKT has a wholly-owned subsidiary in Sweden, with additional operations in the United Kingdom, Canada and South America.

Through its innovative technologies and dedicated team of employees, TKT believes it will make a real difference in people's lives.

View Jobs for Transkaryotic Therapies Inc.